While the mutation profiles of PIK3CA/R1 and PTEN were not correlated across cancer cell lines (as expected, PCC = −0.05), two significant CNA-IC50 concordances were found between the gene mutation settings: for AZD-2281 (olaparib), which targets PARP1/2 and the DNA damage response; and for AZD-8055, which targets mTORC1/2 (Additional file 6). This evidence concerns the gene PARP1 and cancer.